It compares different reversal agents, including pcc (kcentra®), and their mechanisms, onset, duration, and notes. Kcentra and andexxa are both reasonable options for factor xa reversal in major bleeding While andexxa appears to have good hemostatic efficacy, it has greater risk of thrombotic events, specifically cerebrovascular events, compared to kcentra, and no differences in mortality. Patients with acute intracerebral hemorrhage who are receiving factor xa inhibitors have a risk of hematoma expansion The effect of andexanet alfa, an agent that reverses the effects of factor xa. With a paucity of literature comparing the 2 agents, there is clinical.
It was approved by the fda in may 2018 and became commercially available in the first quarter of 2019.
OPEN
